查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1881530

活性藥物成分CDMO市場－全球產業規模、佔有率、趨勢、機會和預測，按分子類型、合成方法、藥物類型、工作流程、應用、地區和競爭格局分類，2020-2030年預測

Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Molecule Type, By Synthesis, By Drug Type, By Workflow, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球活性藥物成分（API）合約開發與生產組織（CDMO）市場規模為9,698萬美元，預計至2030年將以6.1%的複合年成長率成長至1.3835億美元。活性藥物成分（API）合約開發與生產組織（CDMO）以合約形式為製藥公司提供全面的API開發和生產服務，協助其進行藥物合成、製程最佳化、規模化生產和法規遵循。市場成長的主要促進因素包括：不斷增加的藥物研發投入、全球慢性病盛行率的上升（需要新的療法）以及藥物分子日益複雜化。

市場概覽
預測期 2026-2030
2024年市場規模 9698萬美元
2030年市場規模 1.3835億美元
2025-2030年複合年成長率 6.1%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球活性藥物成分CDMO市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依分子類型（小分子、大分子）分類
    • 透過合成（生物技術、合成）
    • 依藥物類型（創新藥、學名藥）
    • 按工作流程（臨床、商業）
    • 依專業方向（心臟科、腫瘤學、眼科學、神經病學、骨科學、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美活性藥物成分CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲活性藥物成分CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區活性藥物成分CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲活性藥物成分CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美活性藥物成分CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球活性藥物成分CDMO市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Cambrex Corporation
  • Thermo Fisher Scientific, Inc.
  • Recipharm AB
  • Corden Pharma International GmbH
  • Samsung Biologics Co., Ltd.
  • Lonza Group Ltd.
  • Siegfried Holding AG
  • Piramal Pharma Limited
  • AbbVie Inc.
  • Catalent, Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 21111

The Global Active Pharmaceutical Ingredients CDMO Market, valued at USD 96.98 Million in 2024, is projected to experience a CAGR of 6.1% to reach USD 138.35 Million by 2030. An Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides comprehensive development and manufacturing services for APIs on a contract basis, assisting pharmaceutical firms with drug substance synthesis, process optimization, scalable production, and regulatory compliance. The market's growth is primarily driven by increasing pharmaceutical research and development investments, the escalating global prevalence of chronic diseases necessitating new therapies, and the growing complexity of drug molecules.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 96.98 Million
Market Size 2030USD 138.35 Million
CAGR 2025-20306.1%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

The robust pharmaceutical research and development pipeline, along with consistent new drug approvals, significantly drives the Global Active Pharmaceutical Ingredients CDMO Market. Substantial industry investment in novel therapies necessitates specialized API development and manufacturing expertise. According to the International Federation of Pharmaceutical Manufacturers & Associations, global pharmaceutical R&D expenditure reached USD 204 billion in 2023, underscoring this commitment to innovation and growth. This sustained investment fuels demand for CDMOs capable of supporting complex early-stage development through commercial scale production. The global API manufacturing landscape features geographically diversified capabilities, crucial for supply chain resilience. For instance, according to the Pacific Forum, in 2022, India housed 18% of global API manufacturing facilities, demonstrating the importance of specialized centers in meeting worldwide demand.

Key Market Challenges

A significant challenge impeding the growth of the Global Active Pharmaceutical Ingredients CDMO Market involves maintaining adequate transparency and control over outsourced production processes. This difficulty can lead to struggles in pinpointing the origin of manufacturing issues, navigating complex supply chains, and potentially causing a loss of critical knowledge for the contracting pharmaceutical company. Without clear visibility and stringent control, pharmaceutical firms face heightened risks regarding product quality and regulatory compliance.

Key Market Trends

The rising outsourcing of biologics and advanced therapies production represents a pivotal trend in the Global Active Pharmaceutical Ingredients CDMO Market. As pharmaceutical companies increasingly focus on complex biopharmaceuticals, including monoclonal antibodies, cell, and gene therapies, the specialized expertise and infrastructure required for their development and manufacturing often necessitate external partnerships. These advanced modalities demand sophisticated facilities, stringent quality control, and specialized technical personnel that many pharmaceutical companies prefer to outsource to dedicated CDMOs. The U. S. Food and Drug Administration (FDA) reported that in 2023, the Center for Biologics Evaluation and Research (CBER) approved 22 new Biologics License Applications (BLAs), nearly doubling the approvals from 2021 and 2022, underscoring the expanding pipeline in this segment.

Key Market Players

  • Cambrex Corporation
  • Thermo Fisher Scientific, Inc.
  • Recipharm AB
  • Corden Pharma International GmbH
  • Samsung Biologics Co., Ltd.
  • Lonza Group Ltd.
  • Siegfried Holding AG
  • Piramal Pharma Limited
  • AbbVie Inc.
  • Catalent, Inc.

Report Scope:

In this report, the Global Active Pharmaceutical Ingredients CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredients CDMO Market, By Molecule Type:

  • Small Molecule
  • Large Molecule

Active Pharmaceutical Ingredients CDMO Market, By Synthesis:

  • Biotech
  • Synthetic

Active Pharmaceutical Ingredients CDMO Market, By Drug Type:

  • Innovative
  • Generics

Active Pharmaceutical Ingredients CDMO Market, By Workflow:

  • Clinical
  • Commercial

Active Pharmaceutical Ingredients CDMO Market, By Application:

  • Cardiology
  • Oncology
  • Ophthalmology
  • Neurology
  • Orthopedic
  • Other

Active Pharmaceutical Ingredients CDMO Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Active Pharmaceutical Ingredients CDMO Market.

Available Customizations:

Global Active Pharmaceutical Ingredients CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Active Pharmaceutical Ingredients CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 5.2.2. By Synthesis (Biotech, Synthetic)
    • 5.2.3. By Drug Type (Innovative, Generics)
    • 5.2.4. By Workflow (Clinical, Commercial)
    • 5.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North America Active Pharmaceutical Ingredients CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Molecule Type
    • 6.2.2. By Synthesis
    • 6.2.3. By Drug Type
    • 6.2.4. By Workflow
    • 6.2.5. By Application
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Active Pharmaceutical Ingredients CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Molecule Type
        • 6.3.1.2.2. By Synthesis
        • 6.3.1.2.3. By Drug Type
        • 6.3.1.2.4. By Workflow
        • 6.3.1.2.5. By Application
    • 6.3.2. Canada Active Pharmaceutical Ingredients CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Molecule Type
        • 6.3.2.2.2. By Synthesis
        • 6.3.2.2.3. By Drug Type
        • 6.3.2.2.4. By Workflow
        • 6.3.2.2.5. By Application
    • 6.3.3. Mexico Active Pharmaceutical Ingredients CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Molecule Type
        • 6.3.3.2.2. By Synthesis
        • 6.3.3.2.3. By Drug Type
        • 6.3.3.2.4. By Workflow
        • 6.3.3.2.5. By Application

7. Europe Active Pharmaceutical Ingredients CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Molecule Type
    • 7.2.2. By Synthesis
    • 7.2.3. By Drug Type
    • 7.2.4. By Workflow
    • 7.2.5. By Application
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Molecule Type
        • 7.3.1.2.2. By Synthesis
        • 7.3.1.2.3. By Drug Type
        • 7.3.1.2.4. By Workflow
        • 7.3.1.2.5. By Application
    • 7.3.2. France Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Molecule Type
        • 7.3.2.2.2. By Synthesis
        • 7.3.2.2.3. By Drug Type
        • 7.3.2.2.4. By Workflow
        • 7.3.2.2.5. By Application
    • 7.3.3. United Kingdom Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Molecule Type
        • 7.3.3.2.2. By Synthesis
        • 7.3.3.2.3. By Drug Type
        • 7.3.3.2.4. By Workflow
        • 7.3.3.2.5. By Application
    • 7.3.4. Italy Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Molecule Type
        • 7.3.4.2.2. By Synthesis
        • 7.3.4.2.3. By Drug Type
        • 7.3.4.2.4. By Workflow
        • 7.3.4.2.5. By Application
    • 7.3.5. Spain Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Molecule Type
        • 7.3.5.2.2. By Synthesis
        • 7.3.5.2.3. By Drug Type
        • 7.3.5.2.4. By Workflow
        • 7.3.5.2.5. By Application

8. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Molecule Type
    • 8.2.2. By Synthesis
    • 8.2.3. By Drug Type
    • 8.2.4. By Workflow
    • 8.2.5. By Application
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Molecule Type
        • 8.3.1.2.2. By Synthesis
        • 8.3.1.2.3. By Drug Type
        • 8.3.1.2.4. By Workflow
        • 8.3.1.2.5. By Application
    • 8.3.2. India Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Molecule Type
        • 8.3.2.2.2. By Synthesis
        • 8.3.2.2.3. By Drug Type
        • 8.3.2.2.4. By Workflow
        • 8.3.2.2.5. By Application
    • 8.3.3. Japan Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Molecule Type
        • 8.3.3.2.2. By Synthesis
        • 8.3.3.2.3. By Drug Type
        • 8.3.3.2.4. By Workflow
        • 8.3.3.2.5. By Application
    • 8.3.4. South Korea Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Molecule Type
        • 8.3.4.2.2. By Synthesis
        • 8.3.4.2.3. By Drug Type
        • 8.3.4.2.4. By Workflow
        • 8.3.4.2.5. By Application
    • 8.3.5. Australia Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Molecule Type
        • 8.3.5.2.2. By Synthesis
        • 8.3.5.2.3. By Drug Type
        • 8.3.5.2.4. By Workflow
        • 8.3.5.2.5. By Application

9. Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Molecule Type
    • 9.2.2. By Synthesis
    • 9.2.3. By Drug Type
    • 9.2.4. By Workflow
    • 9.2.5. By Application
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Active Pharmaceutical Ingredients CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Molecule Type
        • 9.3.1.2.2. By Synthesis
        • 9.3.1.2.3. By Drug Type
        • 9.3.1.2.4. By Workflow
        • 9.3.1.2.5. By Application
    • 9.3.2. UAE Active Pharmaceutical Ingredients CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Molecule Type
        • 9.3.2.2.2. By Synthesis
        • 9.3.2.2.3. By Drug Type
        • 9.3.2.2.4. By Workflow
        • 9.3.2.2.5. By Application
    • 9.3.3. South Africa Active Pharmaceutical Ingredients CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Molecule Type
        • 9.3.3.2.2. By Synthesis
        • 9.3.3.2.3. By Drug Type
        • 9.3.3.2.4. By Workflow
        • 9.3.3.2.5. By Application

10. South America Active Pharmaceutical Ingredients CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Molecule Type
    • 10.2.2. By Synthesis
    • 10.2.3. By Drug Type
    • 10.2.4. By Workflow
    • 10.2.5. By Application
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Active Pharmaceutical Ingredients CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Molecule Type
        • 10.3.1.2.2. By Synthesis
        • 10.3.1.2.3. By Drug Type
        • 10.3.1.2.4. By Workflow
        • 10.3.1.2.5. By Application
    • 10.3.2. Colombia Active Pharmaceutical Ingredients CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Molecule Type
        • 10.3.2.2.2. By Synthesis
        • 10.3.2.2.3. By Drug Type
        • 10.3.2.2.4. By Workflow
        • 10.3.2.2.5. By Application
    • 10.3.3. Argentina Active Pharmaceutical Ingredients CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Molecule Type
        • 10.3.3.2.2. By Synthesis
        • 10.3.3.2.3. By Drug Type
        • 10.3.3.2.4. By Workflow
        • 10.3.3.2.5. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Active Pharmaceutical Ingredients CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cambrex Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific, Inc.
  • 15.3. Recipharm AB
  • 15.4. Corden Pharma International GmbH
  • 15.5. Samsung Biologics Co., Ltd.
  • 15.6. Lonza Group Ltd.
  • 15.7. Siegfried Holding AG
  • 15.8. Piramal Pharma Limited
  • 15.9. AbbVie Inc.
  • 15.10. Catalent, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer